Recent Psoriasis Deals 1. Allergan in $640M Vit

Recent Psoriasis Deals

1. Allergan in $640M Vitae buyout deal as it further expands dermatology pipeline

"Allergan buys into the Fort Washington, PA-based biotech’s dermatology pipeline that includes VTP-43742, a midstage, first-in-class, orally active RORγt (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis, as well as other autoimmune disorders."

http://www.fiercebiotech.com/biotech/allergan...y-pipeline

2. Fumarate makes weight as Xenoport, Dr. Reddy's ink potential $490M deal

"With their new deal nailed down, Dr. Reddy's Laboratories Ltd. is "keenly interested in getting going immediately" in psoriasis with XP23829, the oral fumaric acid ester (a prodrug of monomethyl fumarate), Xenoport Inc. spokeswoman Jackie Cossmon told BioWorld Today."

http://www.bioworld.com/content/fumarate-make...90m-deal-0

3. Purdue Strikes $790 Million Exicure Deal to Diversify

"While Exicure’s gel targets the same biological pathway as AbbVie Inc.’s top-selling psoriasis injection Humira, the gel drug is applied directly to the skin, meaning it doesn’t have to travel through the whole body’s blood system. The drug, called AST-005, is in early-stage trials."

https://www.bloomberg.com/news/articles/2016-...-from-pain

4. AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug

"AbbVie ($ABBV) is handing over $595 million in an upfront payment to partner with Boehringer Ingelheim on its late-stage psoriasis drug, the anti-IL-23 BI 655066."

http://www.fiercebiotech.com/partnering/abbvi...iasis-drug